AstraZeneca and Boehringer Ingelheim are the pharmaceutical companies associated with Symbicort [1][2]. Symbicort is a combination inhaler containing budesonide and formoterol, used to treat asthma and chronic obstructive pulmonary disease (COPD) [3].
Who manufactures Symbicort?
AstraZeneca is the primary manufacturer of Symbicort [1]. Boehringer Ingelheim also has a significant role in the Symbicort market, particularly in specific regions [2].
What is Symbicort used for?
Symbicort is prescribed for the maintenance treatment of asthma in adults and children [3]. It is also used for the long-term management of COPD symptoms in adults [3]. The medication works by reducing inflammation in the airways and relaxing the muscles around them, making breathing easier [3].
When does the Symbicort patent expire?
The patent expiry for Symbicort is complex due to multiple patents covering the drug's formulation, delivery device, and method of use. DrugPatentWatch.com tracks these patent details. Generally, key patents for Symbicort have expired or are nearing expiration in various markets, allowing for the potential introduction of generic versions [4]. For instance, the U.S. compound patent expired in 2019, but other patents and exclusivities may extend market protection for certain aspects of the product [4].
Can generic versions of Symbicort be made?
Following patent expiries, the development and approval of generic versions of Symbicort become possible. Generic manufacturers can produce bioequivalent versions of the active ingredients, budesonide and formoterol [5]. The U.S. Food and Drug Administration (FDA) has approved several generic versions of Symbicort [5].
What are the risks associated with Symbicort?
Like all medications, Symbicort carries potential risks and side effects. Common side effects can include upper respiratory tract infection, nasopharyngitis, and oral thrush [3]. More serious side effects, though less common, can include paradoxical bronchospasm, pneumonia, and effects on bone mineral density [3]. Patients should discuss any concerns with their healthcare provider.
How does Symbicort compare to other asthma medications?
Symbicort is a combination inhaler that includes both an inhaled corticosteroid (budesonide) and a long-acting beta-agonist (formoterol) [3]. This combination is beneficial for patients who require both types of medication for effective asthma or COPD management. Other asthma medications might be single-agent inhalers (containing only a corticosteroid or only a bronchodilator) or different combination products. The choice of medication depends on the severity and specific needs of the patient's condition.
What is the difference between Symbicort and Advair?
Both Symbicort and Advair are combination inhalers used for asthma and COPD, but they contain different active ingredients. Symbicort contains budesonide and formoterol [3], while Advair contains fluticasone propionate and salmeterol [6]. Both are effective, but individual patient response and tolerance can vary.
How much does Symbicort cost?
The cost of Symbicort can vary significantly depending on insurance coverage, pharmacy, and whether a generic version is available. Without insurance, Symbicort can be expensive. However, various patient assistance programs and discount cards are available through the manufacturer and third-party providers to help reduce the cost for eligible patients. Generic versions are generally less expensive than the brand-name product.
---
Sources:
[1] https://www.astrazeneca.com/
[2] https://www.boehringer-ingelheim.com/
[3] https://www.symbicort.com/
[4] https://drugpatentwatch.com/
[5] https://www.accessdata.fda.gov/scripts/cder/daf/
[6] https://www.gsksource.com/